Biogen lays out long-awaited Alzheimer’s data in obscure journal
On Wednesday, Biogen laid it all on the table for its embattled Alzheimer’s drug Aduhelm, publicizing results from two late-stage trials with the drug, but the company chose to do so in a lesser-known publication.
By Angelica Peebles and Robert Langreth, bloomberg
Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after US regulators cleared the treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen and Eisai change agreements on Alzheimer's drug
For subscribers
Biogen's Alzheimer's drug loses subsidies in the US
For subscribers
Biogen slashes price of controversial Alzheimer's drug
For subscribers
